Article
Topiramate (Topamax), a drug commonly prescribed to treat seizures and migraines, can increase the propensity for calcium phosphate kidney stones, according to a study by researchers at the University of Texas Southwestern Medical Center in Dallas.
Topiramate (Topamax), a drug commonly prescribed to treat seizures and migraines, can increase the propensity for calcium phosphate kidney stones, according to a study by researchers at the University of Texas Southwestern Medical Center in Dallas.
“The widespread and escalating use of topiramate emphasizes the importance of considering the long-term impact of this drug on kidney stone formation,” said senior author Khashayar Sakhaee, MD.
The study consisted of two phases. Thirty-two patients being treated with topiramate and 50 normal volunteers were enrolled in a cross-sectional study in which their blood and urine were tested for kidney stone risk. A short-term study also was conducted in seven individuals to assess stone risk before and 3 months after taking topiramate.
Dr. Sakhaee’s group found that taking topiramate long-term-for about 1 year-caused systemic metabolic acidosis as a result of the inability of the kidney to excrete acid. It also increased the urine pH and lowered urine citrate (Am J Kidney Dis 2006; 48:555-63). In the short-term study, urinary calcium and oxalate did not significantly change in people taking the drug.
“There is a legitimate concern for the occurrence of kidney stones with long-term topiramate treatment,” Dr. Sakhaee said. “Studies are needed to explore the optimal measures to prevent kidney stone formation with topiramate use.”
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.